Zoetis
ZTS
Market cap $69B

154.96 USD

-3.84

2.42%

At close Jul 11, 4:00 PM EDT

After hours

154.96

+0.00

0.00%

1 day

-2.42%

5 days

-2.70%

1 month

-6.84%

3 months

3.69%

6 months

-6.83%

Year to date

-4.70%

1 year

-12.82%

5 years

12.04%

10 years

229.42%

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 13,800

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

126% more call options, than puts

Call options by funds: $384M | Put options by funds: $170M

35% more first-time investments, than exits

New positions opened: 165 | Existing positions closed: 122

8% more funds holding in top 10

Funds holding in top 10: 13 [Q4 2024] → 14 (+1) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 741 | Existing positions reduced: 715

0% more funds holding

Funds holding: 1,838 [Q4 2024] → 1,845 (+7) [Q1 2025]

0% less capital invested

Capital invested by funds: $67.9B [Q4 2024] → $67.8B (-$115M) [Q1 2025]

0.37% less ownership

Funds ownership: 92.43% [Q4 2024] → 92.06% (-0.37%) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$160

3%

upside

Avg. target

$180

16%

upside

High target

$210

36%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

Stifel Jonathan Block	3%upside $160	Hold Downgraded	18 Jun 2025
Piper Sandler David Westenberg	36%upside $210	Overweight Maintained	12 May 2025
UBS Andrea Alfonso	10%upside $170	Neutral Maintained	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about ZTS published over the past 30 days

Zacks Investment Research

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or Zoetis (ZTS).

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

The Motley Fool

3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?

I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.

3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?

The Motley Fool

2 Dividend Growth Stocks to Buy and Hold Forever

For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend (if it pays one), and maintains strong growth prospects. Although it's sometimes difficult to find corporations that can do all that over long periods, stocks of this caliber do exist.

2 Dividend Growth Stocks to Buy and Hold Forever

Zoetis: Growth To Continue Thanks To Companion Animals

Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's leadership, scale, and innovation position it well against new competitors. Financials show steady revenue, profit, and dividend growth, with management raising full-year guidance and focusing on expanding key product lines.

Zoetis: Growth To Continue Thanks To Companion Animals

Zacks Investment Research

Here's Why Zoetis (ZTS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Zoetis (ZTS) is a Strong Growth Stock

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentat.

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

Zacks Investment Research

Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?

Zacks Investment Research

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights

Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.

Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights

Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.

The Merck rival faces intense competition that could limit multiple expansion, Stifel analysts say.

Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded.

See News Rankings

Charts implemented using Lightweight Charts™